Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Randomized, Double-

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44393   clinical trials with a EudraCT protocol, of which   7405   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8,896 result(s) found for: Randomized, Double-. Displaying page 177 of 445.
    «« First « Previous 173  174  175  176  177  178  179  180  181  Next» Last»»
    EudraCT Number: 2022-002605-26 Sponsor Protocol Number: SynAct-CS006 Start Date*: 2022-12-22
    Sponsor Name:SynAct Pharma ApS
    Full Title: A two-part, randomized, double-blind, multi-center, placebo-controlled study of the dose-range, safety and efficacy of 4 and 12 weeks of treatment with AP1189 in adult rheumatoid arthritis (RA) pat...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003858-24 Sponsor Protocol Number: 252BN201 Start Date*: 2019-08-13
    Sponsor Name:Biogen Idec Research Limited
    Full Title: A Multicenter, Double-Blind, Multidose, Placebo-Controlled, Randomized, Parallel-Group, Phase 2 Study to Evaluate the Efficacy and Safety of Intravenous BIIB093 for Patients with Brain Contusion
    Medical condition: Brain contusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10052346 Brain contusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003602-31 Sponsor Protocol Number: TRM-201-HA-301 Start Date*: 2021-12-15
    Sponsor Name:Tremeau Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase III Study with a Long-Term, Open-label Extension to Evaluate the Efficacy and Safety of TRM-201 (Rofecoxib) in Patients with He...
    Medical condition: Hemophilic Arthropathy
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005987-23 Sponsor Protocol Number: 77242113PSO2003 Start Date*: 2022-05-13
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2a Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Oral Tablet Formulation of JNJ-77242113 for the Treatment of Mode...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10071117 Plaque psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-004059-18 Sponsor Protocol Number: 17909 Start Date*: 2019-06-27
    Sponsor Name:Bayer AG
    Full Title: A Multicenter, Randomized, Parallel Group, Double Blind, Active and Placebo Controlled Study of BAY 1753011, a Dual V1a/V2 Vasopressin Receptor Antagonist, in Patients with Congestive Heart Failure...
    Medical condition: Heart failure
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) PT (Completed) AT (Completed) PL (Completed) GR (Completed) ES (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001181-15 Sponsor Protocol Number: FIS-002-2019 Start Date*: 2019-09-17
    Sponsor Name:Fulcrum Therapeutics, Inc.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 24-Week, Parallel-Group Study of the Efficacy and Safety of Losmapimod in Treating Subjects with Facioscapulohumeral Muscular Dystrophy (FSHD)
    Medical condition: Facioscapulohumeral Muscular Dystrophy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064087 Facioscapulohumeral muscular dystrophy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-004493-22 Sponsor Protocol Number: AVT04-GL-301 Start Date*: 2021-04-20
    Sponsor Name:Alvotech Swiss AG
    Full Title: A Randomized, Double-blind, Multicenter Study to Demonstrate Equivalent Efficacy and to Compare Safety and Immunogenicity of a Biosimilar Ustekinumab (AVT04) and Stelara® in Patients With Moderate ...
    Medical condition: Moderate to Severe Chronic Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-001657-42 Sponsor Protocol Number: 19140A Start Date*: 2021-06-14
    Sponsor Name:H. Lundbeck A/S
    Full Title: Interventional, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of eptinezumab for the preventive treatment of migraine
    Medical condition: Chronic migraine
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10066636 Chronic migraine LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003724-36 Sponsor Protocol Number: CODIF-008 Start Date*: 2020-04-24
    Sponsor Name:Ole Lander Svendsen
    Full Title: The DENOCHARCOT trial Efficacy of treatment with DENOsumab of an acute CHARCOT foot in patients with diabetes. A multicenter, double-blind, randomized, placebo-controlled trial.
    Medical condition: acute Charcot foot (Charcot arthropathy; ICD-10: DM14.6) in patients with diabetes
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004859 10008408 Charcot arthropathy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2019-002268-28 Sponsor Protocol Number: ULA04 Start Date*: 2020-03-10
    Sponsor Name:Department of Hepatology and Gastroenterology, Aarhus University Hospital
    Full Title: Single-center, randomized, double-blind, placebo-controlled clinical trial for the safety, tolerability and efficacy of ularitide in cirrhosis patients with refractory ascites.
    Medical condition: Liver cirrhosis with refractory ascites.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004871 10024667 Liver cirrhosis LLT
    20.0 10017947 - Gastrointestinal disorders 10003445 Ascites PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002872-42 Sponsor Protocol Number: D9100C00001 Start Date*: 2019-02-18
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and following Chemoradiotherapy Compared to Chemoradiotherap...
    Medical condition: Patient with FIGO Stages IB2 to IIB Node+ and IIIA to IVA with any node. Patients must not have previously received any definitive surgical, radiation, or systemic therapy for cervical cancer and m...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2022-001828-15 Sponsor Protocol Number: SynAct-CS007 Start Date*: 2022-09-14
    Sponsor Name:SynAct Pharma ApS
    Full Title: A double-blind, multi-center, randomized, placebo-controlled study of the safety and efficacy of 12 weeks extended treatment with AP1189 in early rheumatoid arthritis (RA) patients naïve to DMARD t...
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004859 10003268 Arthritis rheumatoid LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-001421-10 Sponsor Protocol Number: 4783-08 Start Date*: 2008-09-06
    Sponsor Name:Synta Pharmaceuticals Corp.
    Full Title: A Randomized, Double-Blind, Phase III Trial of STA-4783 in Combination with Paclitaxel versus Paclitaxel Alone for Treatment of Chemotherapy-Naïve Subjects with Stage IV Metastatic Melanoma
    Medical condition: Stage IV Metastatic Melanoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10027480 Metastatic malignant melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FR (Prematurely Ended) GB (Prematurely Ended) CZ (Completed) IT (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-004694-27 Sponsor Protocol Number: IM011024 Start Date*: 2019-07-23
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of BMS-986165 in Subjects with Moderate to Severe Ulcerative Colitis
    Medical condition: Ulcerative Colitis
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004856 10045365 Ulcerative colitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) PL (Completed) DE (Completed) BE (Completed) CZ (Completed) FR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-003433-41 Sponsor Protocol Number: APHP180583 Start Date*: 2023-08-30
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A prospective, multi-center, double blind randomized trial of fecal microbiota transplantation (FMT) delivered by capsule versus placebo in severe irritable bowel syndrome (IBS) - ICEBOAT (Ibs Caps...
    Medical condition: Adult patients with severe Irritable Bowel Syndrome (IBS) diagnosed
    Disease: Version SOC Term Classification Code Term Level
    20.1 10017947 - Gastrointestinal disorders 10023003 Irritable bowel syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000726-10 Sponsor Protocol Number: ADAPT Start Date*: 2021-06-23
    Sponsor Name:IRCCS- ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI
    Full Title: Evaluating the short-term renal and systemic effects of Dapagliflozin in non-diabetic patients with stage IV CKD at risk of ESKD because of severe renal insufficiency and persistent proteinuria: A ...
    Medical condition: Non-diabetic stage IV Chronic Kidney Disease (CKD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004857 10009119 Chronic renal failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-002633-34 Sponsor Protocol Number: ESK-001-006 Start Date*: 2023-02-07
    Sponsor Name:Alumis Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ESK-001 in Patients with Moderate to Severe Plaque Psoriasis
    Medical condition: Moderate to Severe Plaque Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-002185-32 Sponsor Protocol Number: NST003 Start Date*: 2022-11-21
    Sponsor Name:NeuroSense Therapeutics Ltd
    Full Title: A Phase IIb, Randomized, Multi-center, Multinational, Prospective, Double-Blind, Placebo- Controlled Study, with an Open Label Extension, to Evaluate Safety, Tolerability and Efficacy of PrimeC in ...
    Medical condition: Amyotrophic lateral sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003884-25 Sponsor Protocol Number: 4202-HEM-301 Start Date*: 2021-06-07
    Sponsor Name:Forma Therapeutics, Inc.
    Full Title: An Adaptive, Randomized, Placebo-controlled, Double-blind, Multi-center Study of Oral FT-4202, a Pyruvate Kinase Activator in Patients with Sickle Cell Disease
    Medical condition: sickle cell disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Temporarily Halted) ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2022-001612-25 Sponsor Protocol Number: REP0122 Start Date*: 2022-10-12
    Sponsor Name:DOMPé FARMACEUTICI S.P.A.
    Full Title: Phase 2, proof-of-concept, randomized, double-blinded, placebo-controlled, multicenter study to assess efficacy and safety of reparixin as add-on therapy to standard of care in adult patients with ...
    Medical condition: Acute Respiratory Distress Syndrome
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10001052 Acute respiratory distress syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 173  174  175  176  177  178  179  180  181  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 04 17:31:45 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA